Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 2019 | Supplemental Material + Published
Journal Article Open

Polycystic Ovary Syndrome and Insulin Physiology: An Observational Quantitative Serum Proteomics Study in adolescent, Normal-Weight Females

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with insulin resistance, even in the absence of overweight/obesity. The aim of the present study is to examine the global serum proteomic profile of adolescent, normal‐weight females with PCOS in order to gain novel insight in the association of this endocrine disorder with insulin physiology and to identify novel circulating markers that can guide intervention protocols. Methods: Non‐depleted serum from normal‐weight (BMI: 18–23 kg m^(−2)), adolescent females (13–21 years old) with PCOS (n = 20) is compared to BMI‐ and age‐matched healthy controls (n = 20) using our 3D quantitative proteomics methodology. Serum samples from study participants are randomly pooled to form four biological replicates of females with PCOS and four of healthy controls (n = 5 per sample pool). Results: One‐hundred and twenty‐six proteins are differentially expressed in females with PCOS compared to controls. Gene ontology analysis shows significant enrichment for terms related to inflammatory immune response, metabolism and insulin‐like growth factor receptor signaling pathway. Circulating levels of IGF‐1 and ‐2 and IGFBP‐2, ‐3, and ‐4 are found to be lower in females with PCOS compared to healthy controls. Conclusions: The present serum proteomics study provides insight into the pro‐inflammatory status and insulin dysregulation in young females with PCOS and identifies potential serological markers that can guide early intervention protocols.

Additional Information

© 2019 The Authors. Proteomics – Clinical Application published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Issue Online: 18 September 2019; Version of Record online: 23 April 2019; Accepted manuscript online: 09 April 2019; Manuscript revised: 12 February 2019; Manuscript received: 15 November 2018. A.M. and N.M.A. have contributed equally to this work. Concept and clinical design: A.M., N.M.A., G.P.C., F.B., and S.D.G.; Proteomics analysis: A.M., D.J.G., J.T., A.A., and S.D.G.; Sample procurement and initial evaluation: G.P.C. and F.B.; Data interpretation: A.M., G.P.C., F.B., and S.D.G.; Guided the design and performance of specific aspects of the experiments: M.S.A., N.A., E.D., G.P.C., and F.B.; Wrote the manuscript: A.M., F.B., and S.D.G.; all authors contributed to its revision and final form. This study was financially supported by the Deanship of Scientific Research, Chair for Biomarkers of Chronic Diseases, in King Saud University, Riyadh, Saudi Arabia; the Wessex Cancer Trust, Wessex Medical Research; EU‐FP7/HELLENIC NSRF (BIOEXPLORE); Annual Adventures in Research—University of Southampton; and the EU‐Excellence II—Systems Biology Framework FRA‐SYS (Grant 4072). The authors declare no conflict of interest.

Attached Files

Published - Manousopoulou_et_al-2019-PROTEOMICS_-_Clinical_Applications.pdf

Supplemental Material - prca2062-sup-0001-table1.jpg

Files

Manousopoulou_et_al-2019-PROTEOMICS_-_Clinical_Applications.pdf
Files (3.5 MB)
Name Size Download all
md5:5b53b028a87ddffb4027be98bb0d076a
882.9 kB Preview Download
md5:0dfa4d3e5200c5aa852f31f8c58d0a68
2.6 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 20, 2023